Press Release - No. 2 / 2017
Zealand hosts conference call on March 15 at 4 pm CET to present 2016 full-year results
Copenhagen, March 13, 2017 - Zealand Pharma A/S ("Zealand") (CVR no. 20 04 50 78) announces that it will be hosting a conference call on March 15, 2017 at 4 pm CET/10 am EDT following the announcement of its full-year results and Annual Report 2016.
Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen and Senior Vice President and Chief Financial Officer Mats Blom. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are:
DK standard access +45 3271 1658 U.K. and international +44 (0) 20 3427 1901 U.S. (free dial-in) +1 212 444 0896 Passcode 7623825
A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, http://edge.media-server.com/m/p/ato4d6zr also accessible from the Investor section of Zealand's website ( www.zealandpharma.com ). Participants are advised to register for the webcast approximately 10 minutes before the start. A recording of the event will be made available on the Investor section of Zealand's website following the call.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer Tel: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Senior Vice President, Chief Financial Officer Tel: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates that primarily target specialty diseases with significant unmet needs.
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin ® in the U.S. and Lyxumia ® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus ® ) and is marketed as Soliqua(TM) 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe.
Zealand's pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).
Attachments:
